Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00524368
Registration number
NCT00524368
Ethics application status
Date submitted
30/08/2007
Date registered
3/09/2007
Date last updated
15/02/2013
Titles & IDs
Public title
A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)
Query!
Scientific title
A Randomized, Open-label Trial to Compare the Efficacy, Safety and Tolerability of DRV/Rtv (800mg/100mg) q.d Versus DRV/Rtv (600mg/100mg) b.i.d in Early Treatment-experienced HIV-1 Infected Subjects
Query!
Secondary ID [1]
0
0
TMC114-TiDP31-C229
Query!
Secondary ID [2]
0
0
CR013783
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ODIN
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Human Immunodeficiency Virus - Type 1
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Acquired immune deficiency syndrome (AIDS / HIV)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Darunavir (DRV)
Treatment: Drugs - Ritonavir (rtv)
Experimental: DRV/rtv 800/100 mg once daily - Two 400 mg darunavir (DRV) ie, TMC114 tablets + one 100 mg ritonavir (rtv) capsule once daily.
Experimental: DRV/rtv 600/100 mg twice daily - One 600 mg TMC114 tablet + one 100 mg capsule of rtv twice daily.
Treatment: Drugs: Darunavir (DRV)
DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.
Treatment: Drugs: Ritonavir (rtv)
DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Virological Response at Week 48 (Number of Participants With Plasma Viral Load Less Than 50 Copies/mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Query!
Assessment method [1]
0
0
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response. In all other cases, intermittent values were imputed with nonresponse. Resuppression after confirmed virologic failure was considered as failure in this algorithm.
Query!
Timepoint [1]
0
0
48 Weeks
Query!
Secondary outcome [1]
0
0
Virologic Response at Week 48 (Viral Load Less Than 400 Copies/mL)
Query!
Assessment method [1]
0
0
Number of participants with confirmed plasma viral load less than 400 copies/mL at Week 48.
Query!
Timepoint [1]
0
0
48 weeks
Query!
Secondary outcome [2]
0
0
Change in log10 Viral Load From Baseline at Week 48
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
48 weeks
Query!
Secondary outcome [3]
0
0
Time to Reach First Virologic Response
Query!
Assessment method [3]
0
0
Time (in weeks) to achieve viral load less than 50 copies/mL by the participants.
Query!
Timepoint [3]
0
0
48 weeks
Query!
Secondary outcome [4]
0
0
Time to Loss of Virologic Response
Query!
Assessment method [4]
0
0
Time taken to lose the virologic response ie, plasma viral load less than 50 copies/mL by participants.
Query!
Timepoint [4]
0
0
48 weeks
Query!
Secondary outcome [5]
0
0
Time-averaged Difference (DAVG) of log10 Plasma Viral Load Over 48 Weeks
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
48 weeks
Query!
Secondary outcome [6]
0
0
Change in CD4+ Cell Count From Baseline
Query!
Assessment method [6]
0
0
CD4+ cell count was calculated using the Last Observation Carried Forward (LOCF) algorithm.
Query!
Timepoint [6]
0
0
48 Weeks
Query!
Secondary outcome [7]
0
0
Change From Baseline in Total Functional Assessment of HIV Infection (FAHI) Score
Query!
Assessment method [7]
0
0
The FAHI is a 44-item questionnaire and incorporates 5 functional scales (physical well-being, emotional well-being/living with HIV, functional and global well-being, social well-being, and cognitive functioning). Each scale included several questions (all 5 scales include total 44 questions). For each question, participants gave a score of either 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit) and 4 (very much). Total FAHI imputed score is calculated by adding scores for each question. The range of total FAHI score is 0 to 176. Higher scores indicate worsening.
Query!
Timepoint [7]
0
0
48 weeks
Query!
Secondary outcome [8]
0
0
Percentage of Participants Adherent/Non-adherent to ARV as Determined by Modified Medication Adherence Self Report Inventory (M-MASRI) Questionnaire at Week 48
Query!
Assessment method [8]
0
0
Self-reported adherence to the ARV medications was measured. The M-MASRI asks participants to report the number of doses taken, as well as the number of doses taken during the last 30 days prior to the study visit by means of a horizontal visual analogue scale (VAS) that generates a self-rated percentage of doses of all the ARV medications taken during the past 30 days.
Query!
Timepoint [8]
0
0
48 weeks
Query!
Secondary outcome [9]
0
0
Area Under the Curve From the Time of Study Medication Administration Upto 24 Hour Postdose (AUC24h) of DRV and Rtv
Query!
Assessment method [9]
0
0
Pharmacokinetic parameter AUC24h was assessed from the time of study medication administration upto 24 hour postdose. Population Pharmacokinetic Estimates of DRV and rtv were evaluated.
Query!
Timepoint [9]
0
0
0 hour predose and 1 hour post dose measured at Weeks 4 and 24. Any time point measured at Weeks 8 and 48.
Query!
Secondary outcome [10]
0
0
Predose Plasma Concentration (C0h) of DRV and Rtv.
Query!
Assessment method [10]
0
0
Pharmacokinetic parameter C0h was assessed. Population Pharmacokinetic Estimates of DRV and rtv were evaluated.
Query!
Timepoint [10]
0
0
0 hour predose and 1 hour post dose measured at Weeks 4 and 24. Any time point measured at Weeks 8 and 48
Query!
Secondary outcome [11]
0
0
Number of Participants Developing Mutations at Endpoint
Query!
Assessment method [11]
0
0
Development of Mutations in Virologic Failures (Plasma Viral Load less than 50 Copies/mL) at endpoint.
Query!
Timepoint [11]
0
0
48 weeks
Query!
Eligibility
Key inclusion criteria
- Patients with documented human immunodeficiency virus - Type 1 (HIV-1) infection
- Patients with a viral load greater than 1,000 HIV-1 ribonucleic acid (RNA) copies/mL
- Stable highly active antiretroviral therapy (HAART) regimen for at least 12 weeks at
screening
- In the investigator's opinion, non-nucleoside reverse transcriptase inhibitors
(NNRTIs) are not a valid treatment option, because of the patient's antiretroviral
(ARV) treatment history, ARV resistance testing, medication-taking behavior, safety
and tolerability concerns, or other patient-related factors
- Prescreening or/and screening plasma HIV-1 RNA greater than 1,000 copies/mL on HAART
regimen at screening
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Presence of any currently active conditions that fit the definition of the World
Health Organization (WHO) Clinical Stage 4, with the following exceptions: stable
cutaneous kaposi's sarcoma (ie, no internal organ involvement other than oral lesions)
that is unlikely to require any form of systemic therapy during the study time period,
wasting syndrome
- Patients for whom an investigational ARV is part of the current regimen, with the
following exceptions if applicable (depending on local regulatory approval):
tenofovir, emtricitabine
- Previous or current use of enfuvirtide (ENF), tipranavir and/or DRV
- Life expectancy of less than 12 months
- Pregnant or breast-feeding females
- Any active clinically significant disease (eg, tuberculosis [TB], cardiac dysfunction,
pancreatitis, acute viral infections) or findings during screening of medical history
or physical examination that, in the investigator's opinion, would compromise the
patient's safety or outcome of the study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/10/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
590
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Darlinghurst
Query!
Recruitment hospital [2]
0
0
- Surry Hills
Query!
Recruitment postcode(s) [1]
0
0
- Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
- Surry Hills
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Massachusetts
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Michigan
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New Jersey
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
North Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Ohio
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
South Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
Argentina
Query!
State/province [15]
0
0
Buenos Aires
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Cordoba
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Guernica
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Neuquen
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Rosario
Query!
Country [20]
0
0
Austria
Query!
State/province [20]
0
0
Wien
Query!
Country [21]
0
0
Brazil
Query!
State/province [21]
0
0
Curitiba
Query!
Country [22]
0
0
Brazil
Query!
State/province [22]
0
0
Distrito Barao Geraldo-Campina
Query!
Country [23]
0
0
Brazil
Query!
State/province [23]
0
0
Pinheiros
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Recife
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Rio De Janeiro
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Salvador
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Sao Paulo
Query!
Country [28]
0
0
Chile
Query!
State/province [28]
0
0
Providencia
Query!
Country [29]
0
0
Chile
Query!
State/province [29]
0
0
Santiago
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Lyon
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Nice
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Orleans Cedex 2
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Paris Cedex 10
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Paris Cedex 12
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Paris
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Vandoeuvre Les Nancy
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Berlin
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Köln
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
München
Query!
Country [40]
0
0
Guatemala
Query!
State/province [40]
0
0
Guatemala
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Budapest
Query!
Country [42]
0
0
Malaysia
Query!
State/province [42]
0
0
Ipoh
Query!
Country [43]
0
0
Malaysia
Query!
State/province [43]
0
0
Kuala Lumpur
Query!
Country [44]
0
0
Malaysia
Query!
State/province [44]
0
0
Pulau Pinang
Query!
Country [45]
0
0
Malaysia
Query!
State/province [45]
0
0
Sungai Buloh
Query!
Country [46]
0
0
Panama
Query!
State/province [46]
0
0
Panama
Query!
Country [47]
0
0
Puerto Rico
Query!
State/province [47]
0
0
San Juan
Query!
Country [48]
0
0
Romania
Query!
State/province [48]
0
0
Bucuresti
Query!
Country [49]
0
0
Romania
Query!
State/province [49]
0
0
Constanta
Query!
Country [50]
0
0
Romania
Query!
State/province [50]
0
0
Iasi
Query!
Country [51]
0
0
Romania
Query!
State/province [51]
0
0
Timisoara
Query!
Country [52]
0
0
South Africa
Query!
State/province [52]
0
0
Cape Town
Query!
Country [53]
0
0
South Africa
Query!
State/province [53]
0
0
Cyrildene Johannesburg Gauteng
Query!
Country [54]
0
0
South Africa
Query!
State/province [54]
0
0
Dundee
Query!
Country [55]
0
0
South Africa
Query!
State/province [55]
0
0
Durban
Query!
Country [56]
0
0
South Africa
Query!
State/province [56]
0
0
Houghton, Johannesburg
Query!
Country [57]
0
0
South Africa
Query!
State/province [57]
0
0
Johannesburg
Query!
Country [58]
0
0
South Africa
Query!
State/province [58]
0
0
Pretoria
Query!
Country [59]
0
0
South Africa
Query!
State/province [59]
0
0
Westdene Johannesburg Gauteng
Query!
Country [60]
0
0
Spain
Query!
State/province [60]
0
0
Barcelona N/A
Query!
Country [61]
0
0
Spain
Query!
State/province [61]
0
0
Madrid
Query!
Country [62]
0
0
Taiwan
Query!
State/province [62]
0
0
Kaohsiung County
Query!
Country [63]
0
0
Taiwan
Query!
State/province [63]
0
0
Taichung 407
Query!
Country [64]
0
0
Taiwan
Query!
State/province [64]
0
0
Taipei
Query!
Country [65]
0
0
Thailand
Query!
State/province [65]
0
0
Bangkok
Query!
Country [66]
0
0
Thailand
Query!
State/province [66]
0
0
Chiang Mai
Query!
Country [67]
0
0
Thailand
Query!
State/province [67]
0
0
Khon Kaen
Query!
Country [68]
0
0
Thailand
Query!
State/province [68]
0
0
Nonthaburi
Query!
Country [69]
0
0
United Kingdom
Query!
State/province [69]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Tibotec Pharmaceuticals, Ireland
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to test if being treated with darunavir/ritonavir (DRV/rtv)
800/100 mg daily is as effective as being treated with DRV/rtv 600/100 mg twice daily, in
early antiretroviral (ARV)-experienced patients when given along with selected optimized
background regimen (OBR).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00524368
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Tibotec Pharmaceuticals, Ireland Clinical Trial
Query!
Address
0
0
Tibotec Pharmaceuticals, Ireland
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00524368
Download to PDF